Upstream Bio, Inc.
UPBHealthcare|Biotechnology|US
$3.23
+0.02 (+0.62%)
Tangible Book / Share
$4.97
Cash / Share
$4.79
Clinical Trials (6)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06966479 A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR) | Severe Asthma | P2 | Active | 396 | RCT, Double-blind | Verekitug, Placebo |
| NCT06981078 A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD | Chronic Obstructive Pulmonary Disease | P2 | Active | 666 | RCT, Double-blind | Verekitug |
| NCT06196879 A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT) | Severe Asthma | P2 | Completed | 479 | RCT, Double-blind | Verekitug (UPB-101), Placebo |
| NCT06164704 A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis With Nasal Polyps | P2 | Completed | 81 | RCT, Double-blind | Verekitug (UPB-101), Placebo |
| NCT05653479 Safety and Blood Levels After a Single Injection of UPB-101 in Healthy Japanese and Non-Japanese Non-East Asian Adults | Healthy | P1 | Completed | 32 | RCT, Open-label | UPB-101 |
| NCT05448651 Safety and Biologic Impact (Pharmacodynamics) of Repeated Injections and Increasing Amounts of UPB-101 in Asthmatics | Asthma | P1 | Completed | 32 | RCT, Double-blind | UPB-101, Placebo |